Court denies Sun Pharma’s bid to avoid trial
25-11-2021
Jazz sues Avadel over Xyrem patent
16-11-2021
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
04-02-2021
Michael Vi / Shutterstock.com
Molina Healthcare claims that Jazz Pharmaceuticals delayed generics of its flagship narcolepsy drug Xyrem (sodium oxybate) and hiked the drug prices to increase profits when it was on the verge of bankruptcy.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Antitrust, generics, ANDA, Lupin, Hikma, Jazz Pharmaceuticals, Xyrem
